GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER - Service Hématologie
Welcome,         Profile    Billing    Logout  
 1 Trial 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Drenou, Bernard
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting
3
790
Europe
Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin
The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Follicular Lymphoma
11/28
04/34
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
STAIR, NCT04963946: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia

Recruiting
2
160
Europe
Stop ACA, ACA Continuation
French Innovative Leukemia Organisation
Untreated Chronic Lymphocytic Leukemia
01/26
08/28
VALYM, NCT04842877 / 2020-005225-81: Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Active, not recruiting
2
141
Europe
Valemetostat tosylate, DS-3201b
The Lymphoma Academic Research Organisation, Daiichi Sankyo
Lymphoma, B-Cell
12/24
10/26
NCT01976182: Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia

Completed
2
166
Europe
Methotrexate, Cyclophosphamide
Rennes University Hospital
Large Granular Lymphocytes Leukemia
02/24
10/24
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
COVID19_LLC-MW, NCT04391946: Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19

Completed
N/A
162
Europe
Data registry
French Innovative Leukemia Organisation, Institut de cancérologie Strasbourg Europe
Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease
03/22
03/23
THEMIS, NCT05350826: Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia

Recruiting
N/A
450
Europe
Ambulatory medical assistance
University Hospital, Toulouse
Chronic Lymphoid Leukemia
07/25
07/25
FOLLOW, NCT05590702: French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings

Recruiting
N/A
1000
Europe
First line therapy
French Innovative Leukemia Organisation, AbbVie, AstraZeneca, BeiGene, Janssen-Cilag Ltd.
CLL/SLL
11/25
12/32
Quali-SAT, NCT04779593: Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis

Recruiting
N/A
240
Europe
Clinical examination, SF36 questionnaire, AIMS2_SF questionnaire, WOMAC questionnaire, EQ-5D-5L questionnaire, Blood Sample Complete blood count, Blood Sample Iron panel, Blood Sample Fasting Glucose, Blood sample lipid panel, Blood sample liver panel, Blood sample C reactive protein, Bloodletting - control group, BioBank, Medico-economical, Bloodletting - experimental group
Rennes University Hospital
Haemochromatosis
01/27
01/27
REALYSA, NCT03869619: REal World Data in LYmphoma and Survival in Adults

Recruiting
N/A
6000
Europe
Real-life epidemiological platform of lymphoma in France
Hospices Civils de Lyon, The Lymphoma Academic Research Organisation
Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL))
11/27
11/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Drenou, Bernard
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting
3
790
Europe
Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin
The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Follicular Lymphoma
11/28
04/34
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
STAIR, NCT04963946: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia

Recruiting
2
160
Europe
Stop ACA, ACA Continuation
French Innovative Leukemia Organisation
Untreated Chronic Lymphocytic Leukemia
01/26
08/28
VALYM, NCT04842877 / 2020-005225-81: Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Active, not recruiting
2
141
Europe
Valemetostat tosylate, DS-3201b
The Lymphoma Academic Research Organisation, Daiichi Sankyo
Lymphoma, B-Cell
12/24
10/26
NCT01976182: Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia

Completed
2
166
Europe
Methotrexate, Cyclophosphamide
Rennes University Hospital
Large Granular Lymphocytes Leukemia
02/24
10/24
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
COVID19_LLC-MW, NCT04391946: Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19

Completed
N/A
162
Europe
Data registry
French Innovative Leukemia Organisation, Institut de cancérologie Strasbourg Europe
Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease
03/22
03/23
THEMIS, NCT05350826: Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia

Recruiting
N/A
450
Europe
Ambulatory medical assistance
University Hospital, Toulouse
Chronic Lymphoid Leukemia
07/25
07/25
FOLLOW, NCT05590702: French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings

Recruiting
N/A
1000
Europe
First line therapy
French Innovative Leukemia Organisation, AbbVie, AstraZeneca, BeiGene, Janssen-Cilag Ltd.
CLL/SLL
11/25
12/32
Quali-SAT, NCT04779593: Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis

Recruiting
N/A
240
Europe
Clinical examination, SF36 questionnaire, AIMS2_SF questionnaire, WOMAC questionnaire, EQ-5D-5L questionnaire, Blood Sample Complete blood count, Blood Sample Iron panel, Blood Sample Fasting Glucose, Blood sample lipid panel, Blood sample liver panel, Blood sample C reactive protein, Bloodletting - control group, BioBank, Medico-economical, Bloodletting - experimental group
Rennes University Hospital
Haemochromatosis
01/27
01/27
REALYSA, NCT03869619: REal World Data in LYmphoma and Survival in Adults

Recruiting
N/A
6000
Europe
Real-life epidemiological platform of lymphoma in France
Hospices Civils de Lyon, The Lymphoma Academic Research Organisation
Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL))
11/27
11/27

Download Options